Furthermore, we show that the histone acetylation binding BET proteins are critical to CXCL8 expression and that BET protein inhibitors offer a novel therapeutic option for modulating CXCL8 in asthma and potentially other neutrophilic diseases. Here, CXCL8 is linked to functional neutrophil defect.